

Pentavalent sialic acid conjugates block coxsackievirus A24 variant and human adenovirus type 37 – viruses that cause highly contagious eye infections

Emil Johansson, Rémi Caraballo, Nitesh Mistry, Georg Zoher, Weixing Qian, C. David Andersson, Daniel L. Hurdiss, Naresh Chandra, Rebecca Thompson, Lars Frängsmyr, Thilo Stehle, Niklas Arnberg, and Mikael Elofsson

ACS Chem. Biol., **Just Accepted Manuscript** • DOI: 10.1021/acscchembio.0c00446 • Publication Date (Web): 26 Aug 2020

Downloaded from pubs.acs.org on September 1, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Pentavalent sialic acid conjugates block coxsackievirus A24 variant and human adenovirus type 37 – viruses that cause highly contagious eye infections

Emil Johansson,^{a,b} Rémi Caraballo,^{a,b} Nitesh Mistry,^c Georg Zocher,^d Weixing Qian,^{a,b,e} C. David Andersson,^{a,b} Daniel L. Hurdiss,^f Naresh Chandra,^c Rebecca Thompson,^g Lars Frångsmyr,^c Thilo Stehle,^{d,h} Niklas Arnberg^c and Mikael Elofsson^{*a,b}

Affiliations

^aDepartment of Chemistry, Umeå University, SE90187 Umeå, Sweden.

^bUmeå Centre for Microbial Research, Umeå University, SE90187 Umeå, Sweden.

^cDepartment of Clinical Microbiology, Section of Virology Umeå University, SE90185 Umeå, Sweden.

^dInterfaculty Institute of Biochemistry, University of Tübingen, 72076 Tübingen, Germany.

^eChemical Biology Consortium Sweden, Umeå University, SE90185 Umeå, Sweden.

^fVirology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584CL Utrecht, The Netherlands.

^gAstbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.

^hVanderbilt University School of Medicine, Nashville, Tennessee 37232, USA

*Professor Mikael Elofsson


Address: Department of Chemistry, Umeå University, SE90187 Umeå, Sweden

E-mail: mikael.elofsson@umu.se

ORCID

Mikael Elofsson: orcid.org/0000-0002-3219-4669

Table of contents graphic



ABSTRACT

Coxsackievirus A24 variant (CVA24v) and human adenovirus 37 (HAdV-37) are leading causative agents of the severe and highly contagious ocular infections acute hemorrhagic conjunctivitis and epidemic keratoconjunctivitis, respectively. Currently, neither vaccines nor antiviral agents are available for treating these diseases, which affect millions of individuals worldwide. CVA24v and HAdV-37 utilize sialic acid as attachment receptors facilitating entry into host cells. Previously, we and others have shown that derivatives based on sialic acid are effective in preventing HAdV-37 binding and infection of cells. Here, we designed and synthesized novel pentavalent sialic acid conjugates and studied their inhibitory effect against CVA24v and HAdV-37 binding and infection of human corneal epithelial cells. The pentavalent conjugates are the first reported inhibitors of CVA24v infection, and proved efficient in blocking HAdV-37 binding. Taken together, the pentavalent conjugates presented here form a basis for the development of general inhibitors of these highly contagious ocular pathogens.

INTRODUCTION

Every year millions of individuals around the world are affected by acute conjunctivitis.^{1,2} The disease can be caused by allergens, chemicals, or underlying systemic disease; however, the majority of cases are caused by viruses and bacteria.¹⁻³ Viral conjunctivitis is estimated to cause up to 80% of all cases

of acute conjunctivitis.¹ Acute hemorrhagic conjunctivitis (AHC) and epidemic keratoconjunctivitis (EKC) are severe and highly contagious forms of viral conjunctivitis.^{4,5} AHC is characterized by a sudden onset of ocular pain, foreign body sensation, excessive lacrimation, keratitis, and conjunctivitis.⁶ Many of these symptoms are also shared with EKC and it is difficult to differentiate these diseases in a clinical setting.⁷ The infections are generally self-limited, resolving in one to two weeks, but can become potentially life-threatening in immunocompromised individuals.^{5,8,9} AHC spreads rapidly within communities, affecting up to 50% of the population. As a result, outbreaks can exhaust healthcare resources of affected regions and severely disrupt the economy.^{5,10} To date, neither antiviral agents nor vaccines are available for treating or preventing AHC or EKC.

AHC is predominantly caused by two members of the *Picornaviridae* family, Coxsackievirus A24 variant (CVA24v) and enterovirus 70 (EV70).¹¹ CVA24v has been reported as the principal etiological agent responsible for >10 million cases of AHC worldwide during the last decades, including two pandemics and numerous recurring outbreaks.^{10,12} To facilitate attachment and subsequent entry, members of the *Picornaviridae* engage a range of different cellular receptors including coxsackie and adenovirus receptor (CAR), decay accelerating factor (DAF, CD55), low density lipoprotein receptor (LDL-R), human P-selectin glycoprotein ligand-1 (PSGL-1), heparan sulfate, integrins, intercellular adhesion molecule-1 (ICAM-1), and glycan-containing receptors terminating in 5-*N*-acetyl-neuraminic acid (sialic acid).¹³⁻¹⁷ EV70 is reported to bind DAF and glycans that terminate in α 2,3-linked sialic acid,^{13,16} while CVA24v binds to α 2,3- and α 2,6-linked sialic acids via pentameric binding sites.^{14,15,18} In addition, engagement of the ICAM-1 receptor is essential for coxsackievirus A24 infection, including nonvariant and variant strains of the virus. However, the virulence and pandemic nature of the variant, AHC-causing, strain seems to be linked to an enhanced ability to bind sialic acid.¹⁹ This adaptation has been suggested to enable efficient attachment of CVA24v to corneal and conjunctival cells,¹⁵ and thereby enhance the transmission of viral progeny.¹⁹

EKC is contracted by millions of individuals worldwide every year.²⁰ The disease is caused by members of the *Adenoviridae* family (HAdV-8, -19, -37, -53, -56, and -64), with HAdV-37 serving as a leading causative agent.²¹ EKC-causing human adenoviruses are reported to engage CD46 or CAR, and α 2,3-linked sialic acids to facilitate attachment.^{22,23} More recently, it was established that HAdV-37 binds to glycoproteins containing the GD1a glycan motif via its homotrimeric fiber knobs proteins.²¹

Sialic acid is a highly polar and negatively charged nine-carbon monosaccharide. It is abundantly expressed on the surface of all cell types and serves important roles in mediating or modulating a variety of physiological and pathophysiological processes.²⁴ For a number of diseases, it has been proposed that sialic acid conjugates can be used for therapeutic intervention. However, in general terms development of carbohydrate-based therapeutics is challenging due to poor pharmacological properties imparted by their high polarity, metabolic vulnerability, and low affinity protein-carbohydrate interactions. In addition, preparation of carbohydrates can be both cumbersome and expensive.²⁵ In the case of CVA24v and HAdV-37 many of these downsides can potentially be circumvented by design of multivalent ligands²⁶ intended for topical administration e.g. eye drops, creams, or ointments. Design of multivalent carbohydrate ligands offers an excellent strategy to achieve high avidity binding to *lectins*²⁶⁻²⁸ via the "cluster glycoside effect"²⁷ or proximity/statistical effects²⁸. The cluster effect is caused by the binding of several monosaccharide ligands to several binding sites on the lectin, while the proximity/statistical effect is caused by a slower off-rate of a multivalent ligand in comparison to a monovalent ligand based on reasoning of proximity.²⁸ Pivotal work with Shiga and cholera toxins demonstrated that multivalent carbohydrate ligands tailored to lectin valency and topology produce dramatic enhancements in avidity.^{29,30} The bacterial AB₅ Shiga toxin and radially symmetric multivalent glycoconjugates were further used to develop and validate a quantitative model to analyze thermodynamic parameters of multivalent interactions.³¹

To date, the only substance reported to inhibit attachment of CVA24v to cells is a 13-valent sialic acid human serum albumin conjugate.¹⁵ For HAdV-37, we and others have shown that trivalent and multivalent sialic acid conjugates are potent inhibitors HAdV-37 attachment and infection.³²⁻³⁴ In this study, we developed novel pentavalent sialic acid conjugates with potential to act as general inhibitors of both AHC and EKC. Such inhibitors could be applied via topical administration and used for treatment and prophylactics to alleviate experienced symptoms, and to limit transmission of these highly contagious infections.

RESULTS AND DISCUSSION

Design of pentavalent sialic acid conjugate

We previously reported that trivalent sialic acid conjugates efficiently inhibit HAAdV-37 infection of human corneal epithelial (HCE) cells.^{32,33} These inhibitors were designed to chelate the sialic acid binding sites,³³ which are arranged in a symmetric trimeric fashion in the knob domain of the HAAdV-37 12 fibers protruding from the virus particle. We reasoned that a similar strategy could be applied to CVA24v. In contrast to HAAdV-37, CVA24v has five sialic acid binding sites organized over each of the 12 relatively flat surfaces of the virus particle.¹⁸ Thus, we hypothesized that the sialic acid binding sites of CVA24v could effectively be chelated by pentavalent sialic acid conjugates (Figure 1A). Such pentavalent inhibitors would also have potential to act on HAAdV-37 by providing a high local concentration of sialic acid upon binding to the virion by engaging one to three of the sialic acid binding sites of the fiber knob protein with the non-engaged sialic acids in close proximity (Figure 1B).




Figure 1. Design of pentavalent sialic acid conjugates


A) Schematic representation of a CVA24v particle, and close-up view of one of the pentameric sialic acid binding sites with inhibitor modelled. Inhibitor (purple) with highlight of sialic acid (yellow). B) Schematic representation of a HAAdV-37 particle, and zoom-in of one of the fiber knob proteins that contain trimeric sialic acid binding sites with inhibitor modelled. Inhibitor (purple) with two sialic acids in solution (grey) and three sialic acids binding (yellow). C) Schematic design of the pentavalent sialic acid conjugates. The sialic acid residues are connected to a common core fragment via spacers of sufficient length for chelation of the pentameric binding sites of CVA24v.

Perpropargylated D-glucose was selected as the core fragment (Figure 1C),³⁵ as it allows rapid access to pentavalent sialic acid conjugates via “click” chemistry. Further, glucosides can be accessed in either α - or β -configuration opening an interesting opportunity to study potential differences in binding mode and potency between the two anomers. Two spacer fragments (a polyethylene glycol (PEG) fragment and an amide containing alkyl fragment) were set to contain an azide function in one end and a hydroxyl group in the other. The length of these spacers can be tuned to study the effect of spacer length on potency.^{32,33,36} The design was validated by molecular modelling of pentavalent conjugates **25–28** (Scheme 1) to CVA24v (Figure S1). The resulting complexes were subjected to conformational searches followed by energy minimizations of the spacers. The final conformations were evaluated, and no steric clashes between the conjugates and CVA24v were evident and the carbon-carbon bond lengths and angles showed no strain and were in agreement with benchmark calculations (Table S1). Geometries for the α - and β -configuration of the core were similar with slightly less strain on the latter.

Synthesis of 1st set of pentavalent conjugates

Synthesis of the pentavalent sialic acid conjugates **25–28** was achieved in four steps from the sialic acid donors **1**³⁷ and **2**³⁷ (Scheme 1). The core fragment **19** (α -core) was synthesized by a two-step procedure involving microwave-accelerated Fischer glycosylation of D-glucose using propargyl alcohol,³⁸ followed by O-alkylation³⁵ with an overall yield of 23%. The spacer fragment **3** was synthesized in 95% yield by substituting the corresponding alkylchloride with an azide using NaN₃. Spacer fragment **4** was isolated in 62% yield by coupling 5-amino-1-pentanol with 3-bromopropionyl chloride, followed by azide formation (SI). Donor **1** was sialidated using spacer fragment **3** and **4**, respectively, under promotion of silver trifluoromethanesulfonate and IBr³⁹ affording the corresponding azido acetyl protected sialosides. Subsequent O-deacetylation afforded the α -anomerically pure azido sialosides **11** and **12**, respectively, in 28% and 13% yield over two steps. Compounds **11** and **12** were then “clicked” to the pentapropargylated glucose cores **19** and **20**³⁵ affording the corresponding pentavalent sialic acid

methyl esters **21–24** in 41–73% yields. Subsequent saponification provided the corresponding pentavalent sialic acid conjugates **25–28** in 86% to quantitative yields after neutralization.



Scheme 1. Synthesis of the 1st and 2nd set of pentavalent sialic acid conjugates 25–28 Reagents and conditions: a) i: Molecular sieves (3Å), **3–9**, CH₃CN/CH₂Cl₂ (2:1), rt, 30 min, ii: Silver trifluoromethanesulfonate, 1Br, –74 °C, 5.5 h. b) Sodium methoxide, methanol, rt, 3 h, ii: H⁺ ion exchange resin. c) CuSO₄·5H₂O, sodium ascorbate, tetrahydrofuran/H₂O (1:1), **19** or **20**, 50 °C, 5 h → rt, 18 h. d) i: LiOH, methanol, rt, 24 h, ii: H⁺ ion exchange resin.

Pentavalent sialic acid conjugates inhibit CVA24v attachment to HCE cells

To evaluate the biological effect of the pentavalent conjugates binding inhibition assays were performed.¹⁵ Compared with untreated virions, the attachment of ³⁵S-labeled CVA24v whole virus particles to HCE cells was significantly attenuated when pre-incubated with **25–28** (Figure 2A). All inhibitors were significantly more potent than sialic acid (IC₅₀ >> 2 mM) and disialyllacto-*N*-tetraose (50% reduction in binding at 2 mM).¹⁸ Inhibitors **27** and **28** both containing an amide spacer were equally potent (IC₅₀ 159 μM and 163 μM, respectively), while the PEG based inhibitors **25** and **26** showed lower potency (IC₅₀ 423 μM and 670 μM, respectively). Thus, the inhibitors containing an amide spacer were 3- to 4-fold more potent than inhibitors containing a PEG spacer. All inhibitors showed similar absolute potency to the previously reported 13-valent sialic acid conjugate.¹⁵ However, in terms of relative ligand efficiency, the ratio of the affinity of a ligand divided by the number of heavy atoms in the molecule, **25–28** were significantly more efficient at inhibiting CVA24v attachment.

Pentavalent sialic acid conjugates inhibit CVA24v infection

To further evaluate the biological effect of the pentavalent conjugates, infection assays were performed.³² All four pentavalent conjugates **25–28** inhibited CVA24v virus particles from infecting HCE cells (Figure 2B), thus confirming the trends from the binding assays. Compounds **27–28** were 5- to 11-fold more potent than **25–26**. All inhibitors were significantly more efficient than sialic acid monosaccharide that showed no apparent effect on infection at 4 °C (Figure 2B).

Increasing the temperature to physiological conditions (37 °C) did not significantly alter the effect of the inhibitors on the infection (Figure S2), thus indicating the inhibitors are efficient despite the decreased utilization of sialic acid at increasing temperature by CVA24v.¹⁹




Figure 2. Effect of pentavalent sialic acid conjugates on CVA24v binding and infection of HCE cells and binding of 28 to CVA24v penton

A) Virion binding in presence of inhibitors at different concentrations at 4 °C. B) Infection at different concentrations of inhibitors at 4 °C. Error bars shown as standard error of the mean (SEM). Data are presented as % of control that is the value obtained in the absence of inhibitor. All experiments were performed in duplicates for and a minimum of two times. C) Structure of **28**-CVA24v complex. Observed electron density shown in cage, remaining parts of **28** have been modelled for clarity. D) Interactions of sialic acid moiety of **28** to amino acids in ligand binding site of CVA24v.

X-Ray Crystallography supports binding of the pentavalent sialic acid conjugates to CVA24v

Next, we investigated the binding modes of **25–28** by X-ray crystallography. Structures of all four (**25–28**) inhibitor-CVA24v complexes were established with resolutions up to 1.8 Å. All structures showed clear electron density for the sialic acid in all of the five binding sites, in addition to a couple of the closest spacer atoms. Remaining parts of the inhibitors were not detected, likely due to high flexibility and adaptation of several conformations; these have been modelled into the **28**-CVA24v complex (Figure 2C). The binding of **25–28** is very similar to the binding observed for other glycan-CVA24v structures with most of the contacts retained.¹⁸ The key contributors to inhibitor binding are Ser147, Tyr250, and Tyr145 that directly interact with the sialic acid units of the inhibitors. Ser147 interacts with the carboxylate group of sialic acid by donating hydrogen bonds from its side chain hydroxyl group and its main chain amide proton. The side chain of Tyr250 donates a hydrogen bond and a water-mediated hydrogen bond to the C5-acetamido carbonyl oxygen and the C4 hydroxyl group of sialic acid,

1
2
3
4 respectively. The main chain amido carbonyl of Tyr145 accepts a hydrogen bond from the C5
5 acetamido-NH group of sialic acid. Moreover, a water-mediated hydrogen bond is contributed by the
6 carbonyl oxygen of Pro252. To stabilize the conformation of Tyr145, an extensive π - π stacking network
7 involving Tyr145, Arg254, and Phe95 appears important for enabling contacts to the sialic acid unit.
8 Hydrophobic contacts are also contributed by Tyr145, Ala146, and Pro252 non-polar regions of the
9 binding site. The C9 hydroxyl of the sialic acid entity of **28** engage in intramolecular hydrogen bonding
10 to the carboxylate group causing the glycerol chain to adopt a conformation that previously were
11 observed only as a minor conformation for other glycan containing structures 4Q4X and 4Q4Y (Figure
12 2D).¹⁸ On the basis of the structural data, an explanation to this peculiar interaction could not be
13 determined. The absence of electron density for the core and spacer fragments of **25–28** are in line with
14 previous observations with trivalent sialic acid conjugates containing long and flexible spacer
15 fragments.³² In that case, successive shortening of the spacers, resulted in decreased flexibility and
16 increased potency, eventually resulting in detection of density for entire molecules including spacers
17 and core.³³

18 **Design and synthesis of the 2nd set of pentavalent sialic acid conjugates**

19 The second set of compounds focused on studying the effect of spacer length on potency. Due to their
20 higher potency, inhibitors containing an amide appeared more attractive for probing of a tailor-made
21 chelation of the sialic acid binding sites. Thus, compounds **39–42** containing successively shorter
22 spacers and **43–46** containing longer spacers were designed (Figure 3A). Placement of the amide was
23 probed by moving it closer to the sialic acid residues in compounds **39–42**.

24 Compounds **40** and **46**, containing the shortest and longest amide containing spacers,
25 respectively, were subjected for further evaluation using computational methods (Figure S3 and Table
26 S1). In an analogous manner to the 1st set, modelling of **40** and **46** to CVA24v including conformational
27 searches and energy minimizations, indicated that the spacers were of sufficient length to not cause
28 strain on the spacers; nor were steric clashes with the amino acid backbone of the virion evident (Table
29 S1 and Figure S3, respectively). Thus, the designed compounds **39–46** could be used to probe for the
30 optimal length required for a tailor-made chelation of the binding sites.

31 To challenge the spacer length **47** and **48** were designed (Figure 3A). Modelling of **48** to CVA24v
32 showed severe strain, manifested by a large average C-C-C bond angle of 123.3° (Figure S3 and Table
33 S1). In addition, steric clashes occurred between the aliphatic spacers of **48** and amino acid residues of
34 the virion thus indicating that although possible, simultaneous binding of all five sialic acid residues to
35 the pentameric binding sites of CVA24v is associated with significant energy costs. Therefore, the
36 potency of **48** should be significantly decreased as the length of its spacers are unlikely to be of optimal
37 length for chelating the sialic acid binding sites. In contrast, **47** is unlikely to act as an optimal chelator
38 due to its extended length, and its potency should therefore be reduced as binding is likely associated
39 with large entropic costs due to significant loss of translational and rotational degrees of freedom.³⁶

40 Synthesis of pentavalent conjugates **39–48** was achieved in analogous manner to the synthesis
41 of **25–28**, with minor modifications. The use of donor **2** in combination with decreased concentration of
42 spacer fragment **4** proved beneficial in the synthesis of azido sialoside **12**, improving the yield to 35%
43 over two steps. Therefore, donor **2** was used in the synthesis of azido sialosides **13–18**.




Figure 3. Effect of spacer length on CVA24v and HAd-V37 binding to HCE cells, and effect of 28 on thermal stability of CVA24v. A) CVA24v binding at 4 °C in presence of inhibitors at different concentrations. For clarity, only representative examples from the series of spacer optimized compounds are illustrated in the diagram. Binding inhibition data for all pentavalent sialic acid conjugates **25–28** and **39–48** are summarized in the table and their corresponding curves can be found in Fig. S3. Error bars shown as SEM. Data are presented as % of control that is the value obtained in the absence of inhibitor. All experiments were performed in duplicates for and a minimum of two times. B) Effect of **28** on thermal stability of CVA24v. Fluorescence curves of CVA24v with (solid black line) and without (solid grey line) **28**. The dashed lines correspond to fluorescence of **28** in absence of CVA24v (black), and fluorescence of denatured CVA24v (grey line). Table below graph shows summary of CVA24v T_m and T_m shifts (ΔT_m) as measured for protein (measured by SYPRO orange) and RNA with and without treatment of 100 μM sialic acid, pleconaril, or **28**. All graphs are presented in the SI. C) HAd-V37 binding at 4 °C in presence or absence of inhibitors at different concentrations. Only representative examples from the complete series of spacer optimized pentavalent conjugates were tested, in addition to trivalent sialic acid conjugate **ME0462**³³ used as a control. Error bars in A and C are shown as SEM. Data are presented as % of control that is the value obtained in the absence of inhibitor. All experiments were performed in duplicates for and a minimum of two times.

Spacer length of the conjugates affects the inhibitory potency against CVA24v

The inhibitory effect of the 2nd set of compounds was evaluated in cell binding assays. The most potent compound **44** (IC_{50} 157 μM) was measured to be 1.6-fold more potent than reference compound **28** (IC_{50} 248 μM) (Figure 3A). As expected, **47** (IC_{50} 1.16 mM) and **48** (IC_{50} 1.12 mM) with very long or short spacers were the least efficient of the series proving 5.4- and 4.6-fold less potent than **28** respectively

(Figure 3A). Compounds **39–42**, containing shorter spacers, were 1.8- to 2.1-fold less potent than **28**, while compounds **43–46**, containing longer spacers, were equally or 1.4- to 1.6-fold more potent than **28** (Figure 3A, and Figure S4 for dose-response curves). Thus, increased spacer length resulted in slightly improved potency. Correlation between anomeric configuration of the core and potency could however not be demonstrated. This can potentially be attributed to the absence of direct contacts between the protein backbone of the virion and the spacers and core. Further, the compounds are able to bind with either the α - or the β -face of the core projecting toward the virion thus rendering potential effects of core configuration to a minimum. However, it is possible that the anomeric configuration might play a critical role in combination with a certain linker type and length. On the other hand, a weak correlation between spacer length and potency was observed as compounds with longer spacers were 3- to 4-fold more potent than compounds with shorter spacers. However, greatly increasing the length of the spacer was not beneficial, reflecting the greater entropic costs of binding of a more flexible ligand. Spacer type did not seem to affect potency as compounds **25–26** containing a PEG spacer were equally potent to compounds **41–42** containing an amide spacer of comparable length (Figure 3A).

Crystal structures of all inhibitor-virus complexes were obtained and resolved as previously described, however, similar to the **28**-CVA24v complex (pdb-code 6TSD), density was only observed for the sialic acid units. Thus, decreasing the flexibility of the conjugates by decreasing the spacer length of **39–42** did not lead to detection of additional electron density from the spacer(s) or core(s).

Pentavalent sialic acid conjugates provide mild stabilization of the CVA24v particle

Antiviral drugs targeting the viral capsid have been suggested to act by stabilization of the virus particle,⁴⁰ thereby preventing (or delaying) receptor mediated conformational changes required for uncoating.⁴¹ Pleconaril is one of the most studied capsid-binding molecules and is known to bind to the hydrophobic pocket of most *Enteroviruses* where it replaces the hydrophobic pocket factor (a fatty acid), which stabilizes the virus particle preventing uncoating.^{42,43} Contrarily, capsid-binding molecules could also act by destabilizing the virus particle triggering conformational changes, resulting in early uncoating and inactivation of the virus. To study the effect of the inhibitors on the stability of the CVA24v particle we performed Particle Stability Thermal Release Assay (PaSTRy).⁴⁴ We selected the original inhibitor **28** as a representative example of the synthesized compounds. In addition, we selected pleconaril and sialic acid monosaccharide as controls. The melting temperature (T_m) of the CVA24v particle was calculated to be 48.40 °C for the proteins (T_m protein) and 50.25 °C for release of the viral genome (T_m RNA) (Figure 3B). The melting profile is in the same range as for other known *Enteroviruses*.⁴¹ Treatment of CVA24v with the sialic acid monosaccharide shifted the release of the viral genome to 50.96 °C indicating mild thermal stabilization (Figure S5). For the pleconaril control, the melting temperature shifted to 51.57 °C (Figure S5), which is a relatively weak effect in comparison to other known *Enteroviruses* where pleconaril had a thermal stabilizing effect of 3–6 °C.⁴¹ Similar to pleconaril and sialic acid, compound **28** showed a mild stabilizing effect by shifting the T_m for release of the viral genome to 51.26 °C (Figure 3B). This indicates that the mechanism of inhibition does not involve destabilization of the viral capsid, and early release of the viral genome, upon compound binding.

Pentavalent sialic acid conjugates inhibit HAdV-37 binding to HCE cells

To study the ability of the pentavalent conjugates to act as general inhibitors of AHC and EKC, we performed binding experiments using HAdV-37 and HCE cells.²³ Compared with untreated virions, the attachment of ³⁵S-labeled HAdV-37 to HCE cells was significantly reduced when pre-incubated with **28**, **46** and **48** (Figure 3C). All tested compounds were significantly more potent than the sialic acid monosaccharide (IC_{50} 1.2 mM)³³ and the GD1a glycan (IC_{50} 90.8 μ M).²¹ Compound **48** (IC_{50} 18 nM) was roughly 3.7 orders of magnitude more potent than GD1a, while **28** (IC_{50} 34 nM) and **46** (IC_{50} 192 nM) proved about 2- and 11-fold less effective than **48** respectively.²¹ These results were in agreement with previous observations that multivalent sialic acid conjugates with shorter spacers are more potent against HAdV-37.^{32,33} The pentavalent conjugates were however not as efficient at inhibiting HAdV-37 binding as reference compound **ME0462** (IC_{50} 0.38 nM).³³ **ME0462** has a nearly perfect fit in the fiber knob and our previous data indicate that increasing valency might not improve avidity as suggested by theoretical models.³¹ The relatively modest avidity gains obtained against CVA24v is likely the result of CVA24 engaging multiple receptors on the host cells.^{15,19} Nevertheless, compound **46** and **28** (IC_{50} 177 μ M and 248 μ M against CVA24v, respectively) proved very efficient at inhibiting HAdV-37 supporting the prospects of developing a general inhibitor against two of the major causes of EKC and AHC.

The potency of the compounds toward CVA24v may need further improvement. However, administration is likely possible in millimolar concentrations without adverse side-effects since sialic acid

1
2
3
4 is non-toxic and abundantly expressed throughout the human body. Further, repeated administration of
5 **ME0462** in high doses to rabbits did not result in any toxic reactions or adverse side-effects.³³
6
7

8 **Spacer length of pentavalent conjugates affects binding to CVA24v and HAdV-37**

9 The mechanism of potency enhancements in multivalent ligand systems are suggested to occur via
10 chelation, statistical rebinding, cross-linking and aggregation, or via a combination of these mechanisms.
11 An internal diffusion (bind and slide) mechanism has also been proposed for large systems containing
12 many (sub)ligands.²⁸ We were interested to study if the mechanism of potency enhancement occurred
13 via cross-linking and aggregation. To study this, we performed negative staining electron microscopy
14 experiments with CVA24v and HAdV-37 (Figure 5). Compounds **28**, **46**, and **48** were selected from the
15 set of inhibitors as they present a compromise between spacer length and potency toward both CVA24v
16 and HAdV-37. **ME0462** was selected as a control as an aggregation mechanism seems unlikely due to
17 the short spacers of this compound. Compared with untreated CVA24v (Figure 5, PBS left panel),
18 **ME0462** appears able to break up virion clusters present in the control thus it does not cause
19 aggregation or cross-linking of viral particles (Figure 5, **ME0462** left panel). In contrast, treatment with
20 **28**, **46**, and **48** causes formation of CVA24v aggregates. Moreover, the extent seems to be related to
21 spacer length because larger aggregates were observed after treatment with **46** and **28** (long spacers)
22 in comparison to **48** (Figure 5, **28**, **46**, and **48** of left panel). This indicates that aggregation may be the
23 main mechanism of potency enhancement for the inhibitors in regards to CVA24v. It can therefore not
24 be excluded that the sialic acid density observed in each of the five binding sites the crystal structures
25 originates from more than one pentavalent molecule cross-linking virus particles.

26 For HAdV-37, **ME0462** showed very little to no aggregation or crosslinking of viral particles in
27 comparison to untreated virions (Figure 5, PBS and **ME0462** of right panel). Particles were also
28 predominantly monodispersed after treatment with **28** and **48** (Figure 5, **28** and **48** of right panel).
29 However, substantial aggregation and cross-linking, was observed after treatment with **46** (Figure 5, **46**
30 of right panel). Thus, it is reasonable to speculate that the main mechanism of potency enhancement
31 for **28** and **48** occurs via a statistical rebinding mechanism by providing a high local concentration of
32 sialic acid. This can also explain the slightly increased potency of **48** in comparison to **28** as shorter
33 spacers provide a higher effective local concentration of ligands by a simple reasoning of distance
34 between unbound ligand and binding site. For **46**, it appears that aggregation has major involvement in
35 the mechanism of potency enhancement. In this particular system aggregation does, however, not seem
36 to cause additional enhancement in potency in comparison to a statistical rebinding mechanism.

37 In summary, we find it reasonable to speculate that main mechanism of inhibition for these
38 inhibitors involves binding to the virion thus blocking the virus from interacting with its cognate
39 receptor(s) on the cellular surface. This inhibition mechanism can be complemented by e.g. cross-linking
40 of virus particles were the sialic acid residues and possibly the spacers in one compound bind to two
41 virus particles.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Effect of ME0462 and pentavalent sialic acid conjugates on cross-linking and aggregation of CVA24v and HAdV-37. Left panel shows results of negative staining electron microscopy for CVA24v and right panel for HAdV-37 in PBS buffer or incubated with trivalent (**ME0462**) or pentavalent (**28, 48, 46**) sialic acid conjugates at a final concentration of compounds at 2 mM. Scale bars are visible at the bottom left corner for each image and corresponds to 100 nm for images with CVA24v, and 200 nm for images with HAdV-37.

The sialic acid binding sites of CVA24v and HAdV-37 are different

To further understand the binding of the inhibitors to CVA24v and HAdV-37, and the large differences in potency we analyzed their respective binding sites. The sialic acid binding sites of each virus are located in the interface between two protomers of the biological assembly (pentamer and trimer, respectively). The sialic acid binding sites of HAdV-37 are more recessed and less solvent exposed because they are located on the inner side of the fiber knobs. They are also more rigid since there is less mobility in the loops interacting with sialic acid.³³ In CVA24v, the receptor-engaging loops show a higher degree of mobility, and form very shallow binding sites that are solvent exposed. A comparison

of the total buried surface area (BSA) per sialic acid entity does however show similar values of 160.5 Å² for CVA24v and 150.1 Å² for HAdV-37. In HAdV-37, the sialic acid moiety is recognized by direct contacts with Tyr312, Pro317, and Lys345 and via a water-mediated hydrogen bond to Ser344.³³ A notable difference in the recognition is the presence of a salt bridge between the carboxylate group of sialic acid and Lys345. In the case of CVA24v, this electrostatic interaction is absent and the carboxylate is hydrogen bonded to the amide of Ser147 and intramolecularly to the C9 hydroxyl group of sialic acid (Figure 2D). To fully understand these differences in recognition and their potential contributions to inhibitor potency further studies are required.

Another underlying factor to explain the potency difference could be that HAdV-37 exclusively rely on sialic acid glycans for attachment, while CVA24v engage both sialic acid containing glycans and the co-receptor ICAM-1.¹⁹ In summary, several factors seem to contribute in explaining the lower avidity of the pentavalent conjugates toward CVA24v.

CONCLUSION

In this study, we have presented the first inhibitors of CVA24v infection and demonstrated the inhibitors also effectively block HAdV-37 binding to HCE cells. Thus, the synthesized pentavalent sialic acid conjugates inhibit two of the major causative agents of AHC and EKC, supporting development of general inhibitors against these highly contagious eye infections. Topical administration directly to the target tissue in the eye circumvents many of the challenges facing a compound administered orally. The sialic acid binding sites are located on the virus surface and the inhibitors therefore do not need to permeate any cell membranes, reducing the risk of off-target effects. Furthermore, systemic exposure is likely low reducing the risk for toxicity or other adverse effects originating from systemic distribution. General inhibitors are particularly attractive in this case due to clinical difficulties in distinguishing these infections and their causative agents. Such inhibitors could therefore be applied upon development of the first symptoms to alleviate the infections, limit the spread in the general population, and most importantly to help prevent health care-associated infections of immuno-compromised individuals which can result in potentially life-threatening conditions.

Supporting information

Materials and methods, supplementary text on docking and calculations, figure S1-5, table S1-3, chemical synthesis and analytical data, ¹H-NMR and ¹³C-NMR spectra, references (PDF)

Acknowledgements

We thank the Diamond Light Source Ltd. (Didcot, UK) for beamtime and N. Paterson and M. Williams for their on-site support. The project was funded by a Knut and Alice Wallenberg Foundation grant (KAW; grant reference 2013.0019, to N. A. and M. E.) and by the Baden-Württemberg foundation, Glycobiology program (to T. S.).

Author Contributions

E. J., R. C. and W. Q. synthesized all compounds. C. D. A. performed structure-based design. N. M. and N. C. evaluated the target compounds in cell-based assays. G. Z. performed the crystallography experiments. N. M. and L. F. carried out the thermal stability experiments. D. H. L. and R. T. carried out the electron microscopy studies of aggregation. E. J, R. C., M. E., N. A. and T. S., designed the experiments and analyzed the data together with all other authors. E. J wrote most of the manuscript with contributions from all other authors. All authors have given approval to the final version of the manuscript.

The authors declare no competing interests.

Accession Codes

PDB 6TSD

References

- 1
- 2
- 3
- 4 (1) Azari, A. A., and Barney, N. P. (2013) Conjunctivitis: a systematic review of diagnosis and
- 5 treatment, *JAMA* 310, 1721-1729.
- 6 (2) Uchio, E. (2005) New medical treatment for viral conjunctivitis, *Nippon Ganka Gakkai Zasshi* 109,
- 7 962-984; discussion 985.
- 8 (3) Skevaki, C. L., Galani, I. E., Pararas, M. V., Giannopoulou, K. P., and Tsakris, A. (2011) Treatment of
- 9 viral conjunctivitis with antiviral drugs, *Drugs* 71, 331-347.
- 10 (4) Centers for Disease Control and Prevention. (2013) Adenovirus-associated epidemic
- 11 keratoconjunctivitis outbreaks--four states, 2008-2010, *MMWR* 62, 637-641.
- 12 (5) Zhang, L., Zhao, N., Huang, X., Jin, X., Geng, X., Chan, T.-C., and Liu, S. (2017) Molecular
- 13 epidemiology of acute hemorrhagic conjunctivitis caused by coxsackie A type 24 variant in
- 14 China, 2004–2014, *Sci. Reports* 7, 45202.
- 15 (6) Ghazali, O., Chua, K. B., Ng, K. P., Hooi, P. S., Pallansch, M. A., Oberste, M. S., Chua, K. H., and
- 16 Mak, J. W. (2003) An outbreak of acute haemorrhagic conjunctivitis in Melaka, Malaysia,
- 17 *Singapore Med. J.* 44, 511-516.
- 18 (7) Gonzalez, G., Yawata, N., Aoki, K., and Kitaichi, N. (2019) Challenges in management of epidemic
- 19 keratoconjunctivitis with emerging recombinant human adenoviruses, *J. Clin. Virol.* 112, 1-9.
- 20 (8) Klinger, J. R., Sanchez, M. P., Curtin, L. A., Durkin, M., and Matyas, B. (1998) Multiple cases of life-
- 21 threatening adenovirus pneumonia in a mental health care center, *Am. J. Resp. Crit. Care*
- 22 *Med.* 157, 645-649.
- 23 (9) Huang, G., Yao, W., Yu, W., Mao, L., Sun, H., Yao, W., Tian, J., Wang, L., Bo, Z., Zhu, Z., Zhang, Y.,
- 24 Zhao, Z., and Xu, W. (2014) Outbreak of epidemic keratoconjunctivitis caused by human
- 25 adenovirus type 56, China, 2012, *PLoS One* 9, e110781-e110781.
- 26 (10) Kurokawa, M., Rai, S. K., Ono, K., Gurung, R., and Ruit, S. (2006) Viral investigation of acute
- 27 hemorrhagic conjunctivitis outbreak (2003) in Nepal using molecular methods, *Southeast*
- 28 *Asian J. Trop. Med. Public Health* 37, 904-910.
- 29 (11) Wright, P. W., Strauss, G. H., and Langford, M. P. (1992) Acute hemorrhagic conjunctivitis, *Am.*
- 30 *Fam. Physician* 45, 173-178.
- 31 (12) Oh, M.-d., Park, S., Choi, Y., Kim, H., Lee, K., Park, W., Yoo, Y., Kim, E.-C., and Choe, K. (2003)
- 32 Acute hemorrhagic conjunctivitis caused by coxsackievirus A24 variant, South Korea, 2002,
- 33 *Emerg. Infect. Dis.* 9, 1010-1012.
- 34 (13) Karnaucho, T. M., Tolson, D. L., Harrison, B. A., Altman, E., Lublin, D. M., and Dimock, K. (1996)
- 35 The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55), *J. Virol.* 70,
- 36 5143-5152.
- 37 (14) Mistry, N., Inoue, H., Jamshidi, F., Storm, R. J., Oberste, M. S., and Arnberg, N. (2011)
- 38 Coxsackievirus A24 variant uses sialic acid-containing O-linked glycoconjugates as cellular
- 39 receptors on human ocular cells, *J. Virol.* 85, 11283-11290.
- 40 (15) Nilsson, E. C., Jamshidi, F., Johansson, S. M. C., Oberste, M. S., and Arnberg, N. (2008) Sialic acid
- 41 is a cellular receptor for coxsackievirus A24 variant, an emerging virus with pandemic
- 42 potential, *J. Virol.* 82, 3061.
- 43 (16) Nokhbeh, M. R., Hazra, S., Alexander, D. A., Khan, A., McAllister, M., Suuronen, E. J., Griffith, M.,
- 44 and Dimock, K. (2005) Enterovirus 70 binds to different glycoconjugates containing alpha2,3-
- 45 linked sialic acid on different cell lines, *J. Virol.* 79, 7087-7094.
- 46 (17) Cifuentes, J. O., and Moratorio, G. (2019) Evolutionary and structural overview of human
- 47 picornavirus capsid antibody evasion, *Front. Cell. Infect. Microbiol.* 9, article 283.
- 48 (18) Zocher, G., Mistry, N., Frank, M., Hähnlein-Schick, I., Ekström, J.-O., Arnberg, N., and Stehle, T.
- 49 (2014) A sialic acid binding site in a human picornavirus, *PLoS Path.* 10, e1004401.
- 50 (19) Baggen, J., Hurdiss, D. L., Zocher, G., Mistry, N., Roberts, R. W., Slager, J. J., Guo, H., van Vliet, A.
- 51 L. W., Wahedi, M., Benschop, K., Duizer, E., de Haan, C. A. M., de Vries, E., Casasnovas, J. M.,
- 52 de Groot, R. J., Arnberg, N., Stehle, T., Ranson, N. A., Thibaut, H. J., and van Kuppeveld, F. J.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4 M. (2018) Role of enhanced receptor engagement in the evolution of a pandemic acute
5 hemorrhagic conjunctivitis virus, *Proc. Natl. Acad. Sci. U.S.A.* *115*, 397-402.
- 6 (20) Kaneko, H., Suzutani, T., Aoki, K., Kitaichi, N., Ishida, S., Ishiko, H., Ohashi, T., Okamoto, S.,
7 Nakagawa, H., Hinokuma, R., Asato, Y., Oniki, S., Hashimoto, T., Iida, T., and Ohno, S. (2011)
8 Epidemiological and virological features of epidemic keratoconjunctivitis due to new human
9 adenovirus type 54 in Japan, *Brit. J. Ophthalmol.* *95*, 32-36.
- 10 (21) Nilsson, E. C., Storm, R. J., Bauer, J., Johansson, S. M. C., Lookene, A., Ångström, J., Hedenström,
11 M., Eriksson, T. L., Frängsmyr, L., Rinaldi, S., Willison, H. J., Domellöf, F. P., Stehle, T., and
12 Arnberg, N. (2010) The GD1a glycan is a cellular receptor for adenoviruses causing epidemic
13 keratoconjunctivitis, *Nature Med.* *17*, 105-109.
- 14 (22) Wu, E., Trauger, S. A., Pache, L., Mullen, T. M., von Seggern, D. J., Siuzdak, G., and Nemerow, G.
15 R. (2004) Membrane cofactor protein is a receptor for adenoviruses associated with
16 epidemic keratoconjunctivitis, *J. Virol.* *78*, 3897-3905.
- 17 (23) Arnberg, N., Edlund, K., Kidd, A. H., and Wadell, G. (2000) Adenovirus type 37 uses sialic acid as a
18 cellular receptor, *J. Virol.* *74*, 42-48.
- 19 (24) Varki, A. (2008) Sialic acids in human health and disease, *Trends Mol. Med.* *14*, 351-360.
- 20 (25) Ernst, B., and Magnani, J. L. (2009) From carbohydrate leads to glycomimetic drugs, *Nature Rev.*
21 *Drug Discov.* *8*, 661-677.
- 22 (26) Cecioni, S., Imberty, A., and Vidal, S. (2015) Glycomimetics versus multivalent glycoconjugates
23 for the design of high affinity lectin ligands, *Chem. Rev.* *115*, 525-561.
- 24 (27) Lundquist, J. J., and Toone, E. J. (2002) The cluster glycoside effect, *Chem. Rev.* *102*, 555-578.
- 25 (28) Pieters, R. J. (2009) Maximising multivalency effects in protein-carbohydrate interactions, *Org.*
26 *Biomol. Chem.* *7*, 2013-2025.
- 27 (29) Kitov, P. I., Sadowska, J. M., Mulvey, G., Armstrong, G. D., Ling, H., Pannu, N. S., Read, R. J., and
28 Bundle, D. R. (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate
29 ligands, *Nature* *403*, 669-672.
- 30 (30) Zhang, Z., Merritt, E. A., Ahn, M., Roach, C., Hou, Z., Verlinde, C. L. M. J., Hol, W. G. J., and Fan, E.
31 (2002) Solution and crystallographic studies of branched multivalent ligands that inhibit the
32 receptor-binding of cholera toxin, *J. Am. Chem. Soc.* *124*, 12991-12998.
- 33 (31) Kitov, P. I., and Bundle, D. R. (2003) On the nature of the multivalency effect: A thermodynamic
34 model, *J. Am. Chem. Soc.* *125*, 16271-16284.
- 35 (32) Spjut, S., Qian, W., Bauer, J., Storm, R., Frängsmyr, L., Stehle, T., Arnberg, N., and Elofsson, M.
36 (2011) A potent trivalent sialic acid inhibitor of adenovirus type 37 infection of human
37 corneal cells, *Angew. Chem. Int. Ed. Engl.* *50*, 6519-6521.
- 38 (33) Caraballo, R., Saleeb, M., Bauer, J., Liaci, A. M., Chandra, N., Storm, R. J., Frangsmyr, L., Qian, W.,
39 Stehle, T., Arnberg, N., and Elofsson, M. (2015) Triazole linker-based trivalent sialic acid
40 inhibitors of adenovirus type 37 infection of human corneal epithelial cells, *Org. Biomol.*
41 *Chem.* *13*, 9194-9205.
- 42 (34) Aplanter, K., Marttila, M., Manner, S., Arnberg, N., Sterner, O., and Ellervik, U. (2011) Molecular
43 wipes: application to epidemic keratoconjunctivitis, *J. Med. Chem.* *54*, 6670-6675.
- 44 (35) Ortega-Muñoz, M., Morales-Sanfrutos, J., Perez-Balderas, F., Hernandez-Mateo, F., Giron-
45 Gonzalez, M. a. D., Sevillano-Tripero, N., Salto-Gonzalez, R., and Santoyo-Gonzalez, F. (2007)
46 Click multivalent neoglycoconjugates as synthetic activators in cell adhesion and stimulation
47 of monocyte/macrophage cell lines, *Org. Biomol. Chem.* *5*, 2291-2301.
- 48 (36) Liese, S., and Netz, R. R. (2015) Influence of length and flexibility of spacers on the binding
49 affinity of divalent ligands, *Beilstein J. Org. Chem.* *11*, 804-816.
- 50 (37) Marra, A., and Sinaÿ, P. (1989) Stereoselective synthesis of 2-thioglycosides of N-
51 acetylneuraminic acid, *Carbohydr. Res.* *187*, 35-42.
- 52 (38) Bornaghi, L. F., and Poulsen, S.-A. (2005) Microwave-accelerated Fischer glycosylation,
53 *Tetrahedron Lett.* *46*, 3485-3488.
- 54
55
56
57
58
59
60

- 1
2
3
4 (39) Meijer, A., and Ellervik, U. (2002) Study of interhalogens/silver trifluoromethanesulfonate as
5 promoter systems for high-yielding sialylations, *J. Org. Chem.* **67**, 7407-7412.
6 (40) Tsang, S. K., Danthi, P., Chow, M., and Hogle, J. M. (2000) Stabilization of poliovirus by capsid-
7 binding antiviral drugs is due to entropic effects, *J. Mol. Biol.* **296**, 335-340.
8 (41) Martikainen, M., Salorinne, K., Lahtinen, T., Malola, S., Permi, P., Hakkinen, H., and Marjomaki,
9 V. (2015) Hydrophobic pocket targeting probes for enteroviruses, *Nanoscale* **7**, 17457-17467.
10 (42) Lacroix, C., Laconi, S., Angius, F., Coluccia, A., Silvestri, R., Pompei, R., Neyts, J., and Leyssen, P.
11 (2015) In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity
12 against rhinoviruses, *Viol. J.* **12**, 106-106.
13 (43) Liu, Y., Sheng, J., Fokine, A., Meng, G., Shin, W.-H., Long, F., Kuhn, R. J., Kihara, D., and
14 Rossmann, M. G. (2015) Structure and inhibition of EV-D68, a virus that causes respiratory
15 illness in children, *Science* **347**, 71-74.
16 (44) Walter, T. S., Ren, J., Tuthill, T. J., Rowlands, D. J., Stuart, D. I., and Fry, E. E. (2012) A plate-based
17 high-throughput assay for virus stability and vaccine formulation, *J. Virol. Methods* **185**, 166-
18 170.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60